Product Description
Mechanisms of Action: Global Transcription Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clavis Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Leukemia
Phase 2: Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Melanoma|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia|Colorectal Cancer|Ovarian Cancer|Leukemia
Phase 1: Healthy Volunteers|Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619000830190p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Pain Unspecified |
2021-12-31 |
|||
2006-000868-83 |
2006-000868-83 | N/A |
Completed |
Acute Myeloid Leukemia |
2009-07-02 |
2022-03-12 |
Treatments |
|
NCT01258816 |
CP-4055 | P1 |
Completed |
Leukemia |
2013-05-01 |
2019-03-19 |
Treatments |
|
NCT01783964 |
CP4055-110 | P1 |
Completed |
Healthy Volunteers |
2013-02-01 |
2019-03-19 |
Treatments |
|
2008-008518-38 |
2008-008518-38 | P2 |
Terminated |
Leukemia |
2013-05-07 |
2025-06-13 |
Treatments |
|
NCT01035502 |
CP4055-205 | P2 |
Completed |
Acute Myeloid Leukemia |
2013-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00831636 |
CP4055-204 | P2 |
Completed |
Ovarian Cancer |
2009-11-01 |
2019-03-22 |
Treatments |
|
2007-003323-20 |
CP4055-204 | P2 |
Completed |
Ovarian Cancer |
2009-08-30 |
2022-03-12 |
Treatments |
|
NCT00405743 |
CP4055-106 | P2 |
Completed |
Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome |
2009-05-01 |
2019-03-21 |
Treatments |
|
NCT00498407 |
CP4055-202 | P2 |
Completed |
Colorectal Cancer |
2008-12-01 |
2019-03-21 |
Treatments |
|
NCT00498836 |
CP4055-203 | P2 |
Completed |
Melanoma |
2008-10-01 |
2019-03-21 |
Treatments |
|
2006-006766-41 |
CP4055-202 | P2 |
Completed |
Colorectal Cancer |
2008-09-01 |
2022-03-12 |
Treatments |
|
2007-000915-28 |
CP4055-203 | P2 |
Completed |
Melanoma |
2008-08-25 |
2022-03-12 |
Treatments |
|
2005-000690-22 |
CP4055-201 | P2 |
Completed |
Melanoma |
2006-06-30 |
2022-03-12 |
Treatments |
|
NCT00232726 |
CP4055-201 | P2 |
Completed |
Melanoma |
None |
2019-03-21 |
Treatments |
|
NCT01147939 |
CLAVELA | P3 |
Completed |
Acute Myeloid Leukemia |
2013-02-01 |
2019-03-19 |
Treatments |
|
2009-014445-80 |
2009-014445-80 | P3 |
Active, not recruiting |
Leukemia |
2012-02-16 |
2025-06-08 |
Treatments |
|
ACTRN12611000474954 |
CLAVELA | P3 |
Recruiting |
Leukemia |
None |
2024-11-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|